Glaukos Corporation (GKOS) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents strong financial performance with significant growth in key franchises, a robust balance sheet, and positive guidance. The Q&A highlights confidence in iDose and Epioxa, despite some uncertainties in payer coverage and FDA decisions. The raised guidance and promising pipeline developments further support a positive sentiment. However, some caution is warranted due to potential market headwinds and unclear responses in the Q&A.
Key Financial Performance
Consolidated Net Sales $133.5 million, up 38% on a reported basis or 37% on a constant currency basis year-over-year. The growth was driven by growing iDose TR adoption and utilization, along with broader Interventional Glaucoma initiatives globally.
U.S. Glaucoma Franchise Net Sales $80.8 million, a year-over-year growth of 57%. This was driven by growing contributions from iDose TR, which generated sales of approximately $40 million in the third quarter.
International Glaucoma Franchise Net Sales $29.4 million, a year-over-year growth of 20% on a reported basis and 17% on a constant currency basis. The growth was broad-based as the company scaled its international infrastructure and executed plans to drive MIGS forward as the standard of care globally.
Corneal Health Franchise Net Sales $23.3 million, a year-over-year growth of 13%, including Photrexa net sales of $20.3 million. The growth reflects the continued impact of Photrexa realized revenues as a result of the company's entry into the Medicaid Drug Rebate Program.
Gross Margin Continued gross margin accretion was observed, though specific figures were not provided. This reflects strong execution against strategic priorities and operational efficiency.
Cash and Debt $278 million in cash and no debt, indicating a strong balance sheet.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Epioxa Approval: FDA approved Epioxa, a groundbreaking advancement in corneal cross-linking for keratoconus treatment. It is the first and only FDA-approved topical drug therapy that does not require removal of the corneal epithelium.
iDose TR: iDose TR, a first-of-its-kind intracameral pharmaceutical for glaucoma, generated $40 million in Q3 sales and is gaining commercial momentum.
International Glaucoma Franchise: Net sales of $29.4 million, with 20% year-over-year growth. Commercial launch activities for iStent infinite commenced in key European markets.
Revenue Growth: Record Q3 consolidated net sales of $133.5 million, up 38% year-over-year. Full-year 2025 revenue guidance raised to $490-$495 million.
Operational Efficiency: Gross margin accretion and a strong balance sheet with $278 million in cash and no debt.
Transition to Epioxa: Photrexa will be discontinued in 2026, transitioning to Epioxa as the primary treatment for keratoconus.
New Facility: Groundbreaking of a 200,000 square foot research, development, and manufacturing facility in Huntsville, Alabama.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory hurdles: The company faces challenges related to regulatory approvals and compliance, as evidenced by the detailed discussion of FDA approvals and the transition from Photrexa to Epioxa. These processes are time-consuming and resource-intensive, potentially delaying product launches and impacting revenue.
Market adoption and patient access: Despite the approval of Epioxa, the company acknowledges significant barriers to patient access, including underdiagnosis, misdiagnosis, and reimbursement hurdles. These factors could limit the adoption of new therapies and affect revenue growth.
Competitive pressures: The company operates in a competitive market, particularly in the glaucoma and corneal health segments. The need to maintain and grow market share while introducing new products like Epioxa and iDose TR adds pressure.
Economic uncertainties: Macroeconomic conditions, including foreign currency fluctuations, could impact the company's financial performance and operational costs.
Supply chain and operational risks: The company is investing in a new manufacturing facility, which introduces risks related to construction delays, cost overruns, and operational inefficiencies during the transition.
Strategic execution risks: The transition from Photrexa to Epioxa involves significant strategic and operational changes, including patient education, awareness campaigns, and the establishment of new care networks. Any missteps could impact the success of Epioxa's launch and overall strategic objectives.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for 2025: The company has raised its full-year 2025 net sales guidance range to $490 million to $495 million, up from the previous range of $480 million to $486 million.
Preliminary Revenue Guidance for 2026: The company has introduced a preliminary 2026 revenue guidance range of $600 million to $620 million, factoring in expectations for the continued commercial rollout of iDose TR, the surgical MIGS landscape, the International Glaucoma franchise, and the Corneal Health franchise with the launch of Epioxa.
Epioxa Launch and Transition: Epioxa, a new treatment for keratoconus, is expected to be commercially available in Q1 2026, with a permanent J-code established by July 2026. The company plans to discontinue Photrexa commercial availability following a staged transition process in 2026, prioritizing Epioxa as the primary treatment option.
Investment in Patient Access and Awareness: The company plans to substantially increase investments in patient awareness and access for keratoconus treatment, including enhanced education campaigns, development of a handheld KC screening device, and expanded advocacy partnerships.
Infrastructure Expansion: The company has broken ground on a new 200,000 square foot research, development, and manufacturing facility in Huntsville, Alabama, to support long-term growth and innovation, including the production of Epioxa.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What was the rationale behind the CAC meeting for iDose?
A:The CAC meeting was seen as a step in the process of educating MACs about the significant unmet need that iDose meets for glaucoma patients, the robust FDA and peer-reviewed Level 1 data supporting its utilization, and establishing patient access. Management emphasized the considerable data behind iDose, including FDA approval and peer-reviewed publications, as evidence of its game-changing potential.
Q:What data supports the use of iDose?
A:iDose is supported by two Phase III clinical trials involving over 1,000 patients, a single-arm prospective study in combination with cataract surgery showing significant decreases in intraocular pressure, and ongoing studies comparing iDose with other treatments. These studies aim to validate the incremental and cumulative advantages of iDose.
Q:What are the expectations for Epioxa's pricing and payer coverage?
A:Management expressed confidence in executing with Epioxa's pricing by educating payers on the benefits of the therapy and the costs associated with disease progression. They acknowledged the process of establishing payer coverage and patient access as slow and methodical, with expectations to ramp up gradually through 2026.
Q:What is the preliminary guidance for 2026 revenue, and what are the contributing factors?
A:The preliminary guidance for 2026 revenue is $600 million to $620 million. Management expects contributions from U.S. Glaucoma, International Glaucoma, and the Corneal Health franchise, with Epioxa ramping up and Photrexa transitioning off.
Q:What was the iDose performance in the quarter, and what are the utilization trends?
A:iDose achieved approximately $40 million in sales for the quarter, with growth across all MAC regions. About 80% of volumes came from more established MAC regions. Utilization trends indicate growth in combination with cataract surgery, particularly in regions with established reimbursement.
Q:What is the strategy for Epioxa's market development and education efforts?
A:The strategy involves targeted education and awareness campaigns, leveraging digital platforms, and engaging with optometrists and other primary care providers. Investments will also focus on supporting patients through the insurance process and expanding the site of care network.
Q:What are the expectations for iDose's ramp and market adoption?
A:Management expects a linear ramp for iDose, with potential inflection points as broader utilization grows and market access stabilizes. They remain optimistic about iDose's long-term potential to change the standard of care for glaucoma patients.
Q:What are the plans for Epioxa's site of care network and payer coverage?
A:Epioxa requires new capital equipment, and efforts are underway to establish the site of care network. Payer education and engagement are ongoing, with expectations to navigate payer hurdles and expand coverage throughout 2026.
Q:What is the status of the FDA's decision on iDose reapplications?
A:The PDUFA date for the FDA's decision on iDose reapplications is January 28, 2026. Management is hopeful but not counting on approval for reimplantation, and they are preparing for alternative solutions.
Q:What are the expectations for standalone MIGS practices and market development?
A:Management sees standalone MIGS as a growing area, driven by clinical buy-in and logistical changes in practices. They expect the majority of procedures to shift towards standalone interventional glaucoma over the long term, given the large patient population and clinical need.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the expected mix of standalone versus combination cataract procedures for iDose, the exact payer coverage expectations for Epioxa in 2026, and the precise revenue contributions of Epioxa and iDose to the 2026 guidance. They also did not disclose the exact mix of buy-and-bill versus specialty pharmacy for Photrexa volumes.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Affairs Vice
CEO President
CFO quarter
Colby conference
Filings Quarterly
Instructions replay
Instructions statement
Investors section
Ladies gentleman
Quarterly Results
Quarterly Summary
Relations website
Results section
Summary document
approval efficacy
conference Instructions
conference today
document Investors
effort product
fluctuation statement
gentleman name
name Colby
release Investor
replay Investor
section Quarterly
section Vice
section website
statement expectation
statement today
today Financial
today Instructions
transparency result
website Financials
website reconciliation
website today
GKOS Transcript
Glaukos Corporation (GKOS) Q1 2026 Earnings Call Transcript
Positive4-29
The earnings call highlights strong growth in Corneal Health sales and optimistic guidance, with raised sales projections. The Q&A reveals positive sentiments towards iDose and Epioxa, with plans to expand market access and awareness. Although some uncertainty exists regarding reimbursement timelines, the strategic initiatives and promising market potential for Epioxa and iDose suggest a positive stock price movement over the next two weeks.
Glaukos Corporation (GKOS) Q4 2025 Earnings Call Transcript
Positive2-17
The earnings call indicates strong financial performance with 12% YoY growth in Corneal Health sales and raised revenue guidance for 2025 and 2026. The launch of Epioxa and infrastructure expansion are positive indicators. The Q&A reveals no payer pushback on pricing and expected sequential growth in iDose revenue. However, the lack of clarity on certain metrics and operating expense growth are minor concerns. Overall, the positive elements outweigh the negatives, suggesting a positive stock reaction.
Glaukos Corporation (GKOS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-13
Cabaletta Bio, Inc. (CABA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Neutral12-3
GKOS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
